Why AMR Is Bigger Than a Public Health Problem
Antimicrobial resistance (AMR) is widely recognized as one of the most serious threats to global health. The World Health Organization (WHO) identifies AMR among the top 10 public health challenges facing humanity, owing to both its current burden and the trajectory of its spread.1 This designation places AMR alongside conditions that receive far greater public attention, even though its impact is often less visible and more diffuse.
In 2019, bacterial AMR was associated with an estimated 4.95 million deaths globally, including 1.27 million deaths directly attributable to resistant infections.2 These figures demonstrate that AMR is not merely a concern for the future but a growing contributor to global mortality in the present. As resistance continues to erode the effectiveness of existing therapies, formerly routine infections are becoming more complex, more resource-intensive, and in some cases, untreatable.
Viewing AMR strictly as a clinical or epidemiological issue risks underestimating its danger. Resistant infections do not remain confined to individual patients; they influence how care is delivered, how hospitals allocate resources, and how health systems maintain capacity under strain. The consequences extend well beyond the failure of an individual treatment: longer hospital stays, increased use of intensive care, and higher demand on resources.
For this reason, AMR is more accurately understood as a system-level risk. Its effects reverberate through healthcare delivery, economic productivity, and the broader resilience of society as a whole. Recognizing this shift in perspective is essential. AMR is a structural vulnerability that affects multiple interconnected systems and must be considered alongside other infrastructure risks.
The Hidden Dependency: Modern Medicine Runs on Antibiotics
Modern medicine relies on the premise that antimicrobial therapies will remain effective. Antibiotics do far more than treat infections; they are central to safety across a wide range of routine and advanced medical interventions. Procedures as varied as major surgery, cancer chemotherapy, organ transplantation, and dialysis all rely on the ability to prevent and control infections that arise when natural barriers are breached or immune systems are compromised.
This dependency is structural rather than incidental. Surgical procedures, even when performed under sterile conditions, carry a risk of infection that must be managed prophylactically and therapeutically. Chemotherapy suppresses immune function, which increases susceptibility to opportunistic infections. Transplant recipients require long-term immunosuppression, further elevating that risk. Dialysis patients undergo repeated vascular access and face persistent exposure to potential pathogens. In each case, antibiotics are critical to the viability of these interventions at scale.
As the effectiveness of antibiotics decreases, that protection weakens. Infections become harder to prevent and more difficult to treat, increasing the likelihood of complications, prolonged recovery, or treatment failure. Procedures that are now considered routine begin to carry higher levels of uncertainty and, in some cases, may no longer be feasible within acceptable risk thresholds.
This dynamic shifts the implications of AMR beyond the management of infectious diseases. Undermining the conditions required for their safe and reliable execution places core components of modern healthcare delivery at risk. In this context, antibiotics must be seen as enabling infrastructure for the entire medical system. As resistance spreads, not only are individual therapies compromised, but the operational foundation on which contemporary healthcare depends is as well.
Healthcare Systems Under Strain: Capacity, Not Just Cost
The impact of AMR on healthcare systems is often discussed in terms of cost, but its effects on capacity are just as consequential. Resistant infections are associated with longer hospital stays, greater reliance on intensive care, and increased use of specialized resources, all of which place sustained pressure on systems that are already highly constrained.3,4 These demands are not evenly distributed; they concentrate in high-acuity settings where capacity is limited and difficult to expand quickly.
Increasing resource intensity carries the risk of operational disruption. Outbreaks of resistant pathogens can require hospital ward closures and isolation procedures, diverting staff and equipment and interrupting routine care delivery. Procedures must be delayed or cancelled to contain transmission or to redirect capacity to more urgent needs. These disruptions ripple outward, affecting not only patients with resistant infections but also those awaiting elective or time-sensitive care.
The COVID-19 pandemic provided a clear illustration of how system stress can amplify these dynamics. During the first year of the pandemic, the United States saw a significant increase in antimicrobial-resistant infections, including tens of thousands of deaths associated with healthcare-associated infections.5 Under conditions of strain, infection control practices can be harder to maintain, antibiotic use may increase, and surveillance systems may be disrupted, creating an environment in which resistance can spread more readily.
AMR does more than increase the burden on healthcare systems; it reduces their effective capacity to deliver care. Beds remain occupied longer, staff and resources are diverted, and throughput declines. This pattern resembles infrastructure failure, where systems continue to operate but at diminished efficiency and reliability. As resistance grows, the gap between nominal capacity and functional capacity widens, with direct implications for access, quality, and resilience.
Economic Productivity and System-Wide Cost Escalation
The economic consequences of AMR extend beyond healthcare budgets. At a macroeconomic level, AMR has the potential to slow growth, disrupt labor markets, and exacerbate inequality. World Bank modeling suggests that under high-resistance scenarios, AMR could reduce global gross domestic product by up to 3.8% annually by 2050, with an estimated 28 million additional people pushed into poverty.6 These projections reflect not only the direct costs of treatment but also the broader effects of illness, reduced labor participation, and diminished productivity.
Within healthcare systems, the financial burden can already be measured. In the United States alone, antimicrobial-resistant infections are estimated to cost billions of dollars each year, driven by longer hospital stays, more intensive treatment requirements, and the need for more complex and expensive therapies.7,8 Earlier analyses have also linked AMR to tens of billions of dollars in combined direct healthcare costs and lost productivity, as well as millions of additional hospital days annually.3 These costs are not isolated; they accumulate across payers, providers, and public health systems and compound existing financial pressures.
At the workforce level, AMR contributes to lost working days, reduced labor force participation, and reduced working life expectancy. Resistant infections can prolong illness, delay recovery, and increase the likelihood of complications, all of which affect an individual’s ability to return to work or maintain productivity over time.9 These effects translate into measurable declines in labor output, particularly in scenarios where resistance becomes more widespread.
AMR as a National and Global Security Issue
AMR can no longer be viewed solely through a public health or even an economic lens. Governments increasingly treat it as a component of national and global security, reflecting its potential to disrupt critical systems and undermine preparedness. In the United States, AMR is incorporated into broader health security strategies, with federal agencies emphasizing coordinated, cross-sector responses to mitigate its impact.10 This reflects an understanding that infectious disease threats, including resistant pathogens, can affect not only population health but also institutional stability and crisis response capabilities.
The U.S. Department of Defense has taken this view further, identifying AMR as a factor that can overwhelm response capacity and generate cascading health, economic, and societal consequences.11 Within military contexts, the implications are direct. Resistant infections complicate the treatment of combat-related injuries, increasing the risk of severe outcomes, such as limb loss or death, and can compromise recovery timelines and operational readiness. Ongoing investment in infectious disease research, including AMR, reflects its relevance to maintaining force health and mission effectiveness.
At the international level, AMR has emerged as a priority for multilateral coordination. In 2024, United Nations member states adopted a political declaration committing to intensified action on AMR, including efforts to reduce the global burden of resistant infections.12 This consensus indicates that AMR is not only a technical or clinical challenge but a shared strategic concern with implications for global stability.
This convergence of public health, defense, and international policy perspectives underscores a broader shift in how AMR is understood. Governments are already treating it as a security issue because of its ability to degrade system performance, strain response capacity, and amplify the impact of other crises. While it may not always be explicitly labeled as an infrastructure risk, its effects closely align with those of other threats that compromise the reliability and resilience of essential systems.
Reframing AMR: A System-Level Infrastructure Risk
The evidence shows a pattern of AMR impacts that span multiple systems beyond its clinical and epidemiological dimensions. AMR increases the cost of care, reduces the effective capacity of healthcare delivery, disrupts routine operations, diminishes workforce productivity, and carries implications for national and global security.
These effects do not occur in isolation. Longer hospital stays and greater resource intensity constrain bed availability and staff capacity. Operational disruptions, such as ward closures or delayed procedures, reduce throughput and limit access to care. At the same time, increased illness and prolonged recovery reduce labor force participation and productivity, thereby reinforcing the economic burden. Security concerns add another layer, as resistant infections complicate emergency response and strain institutional readiness.
These dynamics resemble the failure modes observed in other forms of infrastructure degradation. Systems continue to function, but with reduced efficiency, diminished reliability, and less resilience to external shocks. The gap between nominal and functional capacity widens, making the system more vulnerable to disruption under stress.
Viewing AMR as an infrastructure risk captures this interconnected pattern. Antibiotics serve as enabling components of modern healthcare and, by extension, of broader economic and social systems. As their effectiveness declines, the systems that depend on them lose stability and performance. Recognizing AMR in these terms clarifies why its impact extends far beyond infection control and why addressing it requires coordinated action across healthcare, economic policy, and security domains.
Protecting Antibiotics Means Protecting System Capacity
Antibiotics are not simply another class of therapeutics. They enable the safe delivery of modern medicine and support the reliable functioning of healthcare systems, economies, and institutions. As AMR advances, that enabling role comes under increasing strain.
These pressures do not remain contained. They accumulate across systems, reducing efficiency in routine conditions and limiting the ability to respond to disruption. What is at risk is not only the effectiveness of individual treatments but the capacity of interconnected systems to operate as intended.
Efforts to address AMR must evolve beyond a narrow focus on stewardship and drug development alone. They require coordinated action across healthcare delivery, public health infrastructure, economic policy, and security planning.
A central challenge in addressing antimicrobial resistance is the misalignment between the nature of the risk and the structure of responses. The benefits of preserving antibiotic effectiveness manifest at the system level over long time horizons, but incentives are often defined at the level of individual institutions, products, or short-term policy cycles. Pharmaceutical innovation is constrained by limited commercial returns for antibiotics that must be used sparingly, while healthcare providers face immediate clinical and financial pressures that favor broader, precautionary use. At the policy level, interventions must be considered within electoral and budgetary cycles that align poorly with the slow progression of resistance. At the same time, responsibility for AMR is distributed across healthcare, agriculture, public health, and environmental systems, with no single entity accountable for managing its full impact.
This fragmentation complicates coordination and limits the ability to implement sustained, system-wide strategies. Current approaches tend to address individual components of the problem rather than the underlying conditions that allow resistance to accumulate, limiting their effectiveness in preserving antibiotic function as a shared infrastructure resource. They require coordinated action across healthcare delivery, public health infrastructure, economic policy, and security planning. Antibiotic effectiveness must be treated as a shared, finite resource that underpins critical system performance.
Protecting that resource is therefore a matter of system preservation. Maintaining antibiotic effectiveness means sustaining healthcare capacity, supporting economic productivity, and ensuring resilience in the face of future shocks. Recognizing AMR in these terms clarifies both the scale of the challenge and the urgency of response.
